David Westenberg
Stock Analyst at Piper Sandler
(3.69)
# 887
Out of 4,412 analysts
106
Total ratings
44.87%
Success rate
8.15%
Average return
Main Sectors:
20 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZTS Zoetis | Reiterates: Overweight | $220 → $195 | $158.42 | +23.09% | 7 | Apr 16, 2024 | |
| NEOG Neogen | Maintains: Neutral | $19 → $17 | $12.14 | +40.03% | 8 | Apr 15, 2024 | |
| ELAN Elanco Animal Health | Reiterates: Neutral | $12 → $18 | $13.26 | +35.75% | 6 | Mar 12, 2024 | |
| NTRA Natera | Maintains: Overweight | $70 → $110 | $91.66 | +20.01% | 9 | Mar 6, 2024 | |
| FLGT Fulgent Genetics | Maintains: Neutral | $28 → $25 | $20.10 | +24.38% | 5 | Mar 6, 2024 | |
| CTKB Cytek Biosciences | Maintains: Overweight | $11 → $10 | $5.76 | +73.61% | 5 | Mar 6, 2024 | |
| NEO NeoGenomics | Maintains: Overweight | $18 → $20 | $14.14 | +41.44% | 7 | Feb 26, 2024 | |
| GH Guardant Health | Maintains: Overweight | $40 → $30 | $17.35 | +72.91% | 6 | Feb 26, 2024 | |
| IDXX IDEXX Laboratories | Downgrades: Neutral | $525 | $499.30 | +5.15% | 5 | Jan 30, 2024 | |
| OCX OncoCyte | Maintains: Neutral | $3.5 → $3 | $2.48 | +20.97% | 7 | Nov 13, 2023 | |
| ILMN Illumina | Maintains: Overweight | $200 → $190 | $122.28 | +55.38% | 11 | Nov 13, 2023 | |
| AKYA Akoya Biosciences | Maintains: Overweight | $11 → $8 | $3.80 | +110.53% | 5 | Nov 13, 2023 | |
| ADPT Adaptive Biotechnologies | Maintains: Overweight | $13 → $6 | $2.60 | +130.77% | 7 | Nov 13, 2023 | |
| PACB Pacific Biosciences of California | Maintains: Neutral | $9 → $8 | $1.47 | +444.22% | 4 | Nov 6, 2023 | |
| DGX Quest Diagnostics | Maintains: Neutral | $130 → $140 | $134.26 | +4.28% | 3 | Nov 6, 2023 | |
| EXAS Exact Sciences | Maintains: Overweight | $90 → $80 | $58.85 | +35.94% | 7 | Oct 16, 2023 | |
| PETQ PetIQ | Maintains: Buy | n/a | $16.53 | - | 1 | Jun 25, 2020 | |
| TXG 10x Genomics | Initiates: Buy | n/a | $27.59 | - | 1 | Mar 5, 2020 | |
| QDEL QuidelOrtho | Upgrades: Buy | n/a | $39.64 | - | 1 | Jan 4, 2018 | |
| TRUP Trupanion | Initiates: Neutral | n/a | $24.12 | - | 1 | Nov 21, 2017 |
Zoetis
Apr 16, 2024
Reiterates: Overweight
Price Target: $220 → $195
Current: $158.42
Upside: +23.09%
Neogen
Apr 15, 2024
Maintains: Neutral
Price Target: $19 → $17
Current: $12.14
Upside: +40.03%
Elanco Animal Health
Mar 12, 2024
Reiterates: Neutral
Price Target: $12 → $18
Current: $13.26
Upside: +35.75%
Natera
Mar 6, 2024
Maintains: Overweight
Price Target: $70 → $110
Current: $91.66
Upside: +20.01%
Fulgent Genetics
Mar 6, 2024
Maintains: Neutral
Price Target: $28 → $25
Current: $20.10
Upside: +24.38%
Cytek Biosciences
Mar 6, 2024
Maintains: Overweight
Price Target: $11 → $10
Current: $5.76
Upside: +73.61%
NeoGenomics
Feb 26, 2024
Maintains: Overweight
Price Target: $18 → $20
Current: $14.14
Upside: +41.44%
Guardant Health
Feb 26, 2024
Maintains: Overweight
Price Target: $40 → $30
Current: $17.35
Upside: +72.91%
IDEXX Laboratories
Jan 30, 2024
Downgrades: Neutral
Price Target: $525
Current: $499.30
Upside: +5.15%
OncoCyte
Nov 13, 2023
Maintains: Neutral
Price Target: $3.5 → $3
Current: $2.48
Upside: +20.97%
Illumina
Nov 13, 2023
Maintains: Overweight
Price Target: $200 → $190
Current: $122.28
Upside: +55.38%
Akoya Biosciences
Nov 13, 2023
Maintains: Overweight
Price Target: $11 → $8
Current: $3.80
Upside: +110.53%
Adaptive Biotechnologies
Nov 13, 2023
Maintains: Overweight
Price Target: $13 → $6
Current: $2.60
Upside: +130.77%
Pacific Biosciences of California
Nov 6, 2023
Maintains: Neutral
Price Target: $9 → $8
Current: $1.47
Upside: +444.22%
Quest Diagnostics
Nov 6, 2023
Maintains: Neutral
Price Target: $130 → $140
Current: $134.26
Upside: +4.28%
Exact Sciences
Oct 16, 2023
Maintains: Overweight
Price Target: $90 → $80
Current: $58.85
Upside: +35.94%
PetIQ
Jun 25, 2020
Maintains: Buy
Price Target: n/a
Current: $16.53
Upside: -
10x Genomics
Mar 5, 2020
Initiates: Buy
Price Target: n/a
Current: $27.59
Upside: -
QuidelOrtho
Jan 4, 2018
Upgrades: Buy
Price Target: n/a
Current: $39.64
Upside: -
Trupanion
Nov 21, 2017
Initiates: Neutral
Price Target: n/a
Current: $24.12
Upside: -